There are different ways to get these medications into your body. Some cytokines such as interleukin-17 (IL-17), interleukin-12 (IL-12), and interleukin-23 (IL-23) are important for adaptive immunity as well. We have medications to remove B cells and to slow down B cells and T cells. Parts of the adaptive immune system are also targets to treat autoimmune disease. If the immune system is working well, the body then remembers that bacteria or virus after fighting off the first infection. When the body sees a new bacteria or virus, it makes T cells and B cells that recognize the invader and help the body to get rid of the infection. Two types of white blood cells called T cells and B cells are important parts of adaptive immunity. The adaptive immune system develops over time. These cytokines, such as tumor necrosis factor (TNF), interleukin-1 (IL-1), and interleukin-6 (IL-6) can be targeted to treat autoimmune disease, where the immune system attacks the body’s own cells. Immune cells make molecules called cytokines to communicate between different parts of the body. These defenses include cells and molecules located at sites of entry for foreign invaders (the nose, lungs, gut, and skin). The innate immune system is the first line of defense against bacteria and viruses. The immune system has two parts: innate and adaptive. Here, we will discuss a wide range of medications used to treat autoimmune disease, the components of the immune system targeted by these medications, and the kinds of infections (if any) that may be more common in people taking these immune suppressive medications. How each of these drugs target specific parts of the immune system may make the patient more likely to get certain infections. The treatments may weaken the entire immune system or only very specific parts of it. The drugs to treat autoimmune and allergic disease target different components of the immune system. Diseases in allergy, immunology, and rheumatology are often caused by problems with the immune system.
0 Comments
Leave a Reply. |